Pharmacodynamics of SMP-601 (PTZ601) against vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in neutropenic murine thigh infection models

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3391-3398

  Eguchi, Ken ^a   Kanazawa, Katsunori ^a   Eriguchi, Yoshiro ^a   Ueda, Yutaka ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CARRAGEENAN; PTZ 601; SMP 601; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; THIGH; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CARRAGEENAN; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; STAPHYLOCOCCAL INFECTIONS; THIGH; VANCOMYCIN RESISTANCE;

EID: 67749111747     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00972-08     Document Type: Article

References (24)

1. Andes, D., and W. A. Craig. 2006. In vivo pharmacodynamic activity of a new carbapenem, PZ601, against multiple bacteria in murine thigh and lung infection models, abstr. F1-232, p. 199. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., American Society for Microbiology, Washington, DC.
2. Chambers, H. F. 2005. Community-associated MRSA resistance and virulence converge. N. Engl. J. Med. 352:1485-1487.
3. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved standard M26-A. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. CLSI, Wayne, PA.
5. Craig, W. A. 1993. Relevance of animal models for clinical treatment. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):S55-S57.
6. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
7. Dandekar, P. K., P. R. Tessier, P. Williams, C. H. Nightingale, and D. P. Nicolau. 2003. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 52:405-411.
8. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36:S42-S50.
9. Eguchi, K., and K. Kanazawa. 2007. In vivo pharmacodynamic activity of SMP-601 (PZ-601) in a new VRE thigh infection model using carrageenantreated mice, abstr. F1-349. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Goldmann, O., M. Rohde, G. S. Chhatwal, and E. Medina. 2004. Role of macrophages in host resistance to group A streptococci. Infect. Immun. 72:2956-2963.
11. Jones, R. N. 2001. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119:397S-404S.
12. Kijima, K., Y. Takayama, J. Nagura, Y. Tanaka, M. Kurazono, K. Yamada, T. Sugano, H. Takata, E. Shitara, and M. Yonezawa. 2004. ME1036 (CP5609), a novel parenteral carbapenem: pharmacokinetics and in vivo pharmacodynamic activities against methicillin-resistant Staphylococcus aureus in a murine thigh infection model, abstr. F-332, p. 197. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
13. Kuti, J. L., P. K. Dandekar, C. H. Nightingale, and D. P. Nicolau. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43:1116-1123.
14. Maglio, D., M. A. Banevicius, C. Sutherland, C. Babalola, C. H. Nightingale, and D. P. Nicolau. 2005. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob. Agents Chemother. 49:276-280.
15. Moellering, R. C., Jr. 2006. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 144:368-370.
16. Rice, L. B. 2006. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control 34:S11-S73.
17. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
18. Sosroseno, W., and E. Herminajeng. 2002. The role of macrophages in the induction of murine immune response to Actinobacillus actinomycetemcomitans. J. Med. Microbiol. 51:581-588.
19. Sunagawa, M., M. Itoh, K. Kubota, A. Sasaki, Y. Ueda, P. Angehrn, A. Bourson, E. Goetschi, P. Hebeisen, and R. L. Then. 2002. New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1β-methyl-2-(thiazol-2-ylthio)carbapenems. J. Antibiot. (Tokyo) 55:722-757.
20. Takata, T., K. Aizawa, A. Shimizu, S. Sakakibara, H. Watabe, and K. Totsuka. 2004. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J. Infect. Chemother. 10: 76-85.
21. Turnidge, J. D. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22.
22. Udono, H., D. L. Levey, and P. K. Srivastava. 1994. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci. USA 91:3077-3081.
23. Ueda, Y., K. Kanazawa, K. Eguchi, K. Takemoto, Y. Eriguchi, and M. Sunagawa. 2005. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob. Agents Chemother. 49:4185-4196.
24. Yamazaki, K., T. Nguyen, and E. R. Podack. 1999. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. 163:5178-5182.